Cannabics Announces New Corporate Logo, New Website and New Company Presentation

Rhea-AI Summary

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has announced a refreshed corporate image, including a new logo and website, as of September 30, 2021. This update aligns with the company’s strategic shift from pre-clinical to clinical stage development, focusing on FDA compliance. The new website, www.cannabics.com, features details on drug candidates and corporate news vital for investors. The update also includes a new corporate presentation showcasing Cannabics' ongoing developments in cannabinoid-based medicine.

Positive

• New corporate logo and website reflect strategic shift to clinical stage.
• Website provides updated information on drug candidates and clinical paths.
• New corporate presentation available for investors.

Negative

• None.

TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website. In addition, the company announced that a new corporate presentation is now available on its new website.

These updates more fully reflect the company's strategic shift from a pre-clinical stage company towards now becoming a clinical stage development corporation focused primarily on FDA regulatory compliance.

The updated site, www.cannabics.com, provides current details on each of the company's drug candidates and their corresponding clinical path. As always, the site offers current news and investor information, including press releases, SEC filings and the newly updated company presentation featuring the latest on Cannabics development.

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Read more:

Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).

Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
info@Cannabics.com
http://www.Cannabics.com

Related Links
https://www.cannabics.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cannabics-announces-new-corporate-logo-new-website-and-new-company-presentation-301388844.html

SOURCE Cannabics Pharmaceuticals Inc.

FAQ

What is Cannabics Pharmaceuticals' new corporate strategy as of September 30, 2021?

Cannabics Pharmaceuticals is shifting its focus from pre-clinical to clinical stage development, emphasizing FDA regulatory compliance.

Where can I find more information on Cannabics Pharmaceuticals' drug candidates?

Updated information can be found on Cannabics Pharmaceuticals' new website at www.cannabics.com.

What updates were made to Cannabics Pharmaceuticals' corporate presentation?

The corporate presentation now includes the latest developments in Cannabics Pharmaceuticals' drug candidates.

What is the significance of Cannabics Pharmaceuticals' new logo and website?

The new logo and website signify a strategic rebranding reflecting the company’s transition to a clinical stage corporation.